First AD

Second AD

Balazs Halmos, MD, is the director of Thoracic Oncology and the director of Clinical Cancer Genomics at Albert Einstein College of Medicine, Montefiore Einstein

Panelists discuss how, after the MARIPOSA regimen, second-line therapy selection depends on resistance mechanisms, prior toxicity, and patient factors. MARIPOSA-2 vs PALOMA-3 choices are influenced by efficacy in resistant mutations and safety profiles, per European Society for Medical Oncology 2023/2024 and American Society of Clinical Oncology 2024 data.

Treatment Sequencing in Disease Progression in EGFRm NSCLC

Video content above is prompted by the following: 

Looking at treatment sequencing, how do you approach second-line therapy after:

What factors influence your choice between MARIPOSA-2 and PALOMA-3?

MARIPOSA-2: Passaro A, et al. ESMO Congress 2023. Abs LBA15, Popat S, et al. ESMO 2024. Abs LBA54.

PALOMA-3: Leighl NB, et al. ASCO 2024. Abs LBA8505.

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 